MARKETS / NASDAQ / PCRX

NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP

Pacira BioSciences, Inc. PCRX

17 fiscal years on record · USD · FY2025 reported · SEC filings only

Revenue

$726.4M

▲ 3.6% YoY

Net income

$7.0M

Free cash flow

$136.7M

▼ 23.5% YoY

In brief

What this company does

It manufactures EXPAREL and iovera handpieces at its facility in San Diego, California. It had three wholesalers each comprising 10 percent or more of its total revenue for the year ended December 31, 2025 -- McKesson Drug Company, Cardinal Health, Inc. and AmerisourceBergen Health Corporation -- which accounted for 31%, 26% and 22% of its total revenues, respectively. It was incorporated in Delaware under the name Blue Acquisition Corp. in December 2006, and changed its name to Pacira, Inc. in June 2007, to Pacira Pharmaceuticals, Inc. in October 2010, and to Pacira BioSciences, Inc. in April 2019.

Written from the business description in Pacira BioSciences, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 26 February 2026. Every sentence was checked against that document before publication.

Growth

USD 726.4M

Revenue, FY2025 · full 17-year series below

Revenue $M Net income $M

FY2025 · Revenue 726.4 · Net income 7.0

Compound annual growth

Revenue

+2.9%

+11.1%

+11.3%

+29.8%

Net income

−23.8%

−45.4%

+14.3%

EPS, diluted

−22.2%

−45.5%

+14.9%

3 yrs

5 yrs

10 yrs

15 yrs

Revenue compounded at +11.1% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

1 cents

of every revenue dollar became profit

Operating margin Net margin

FY2025 · Operating 2.6% · Net 1.0%

ROE

FY2025 · ROE 1.0%

Gross margin79.4%

Operating margin2.6%

Net margin1.0%

Return on assets0.5%

EBITDAUSD 110.2M

Each USD of equity produced 1 cents of profit this year.

Cash & shareholders

USD 147.8M

returned in FY2025 · dividends + net buybacks

Free cash flow $M

FY2025 · FCF 136.7

Net buybacks $M Dividends $M

FY2025 · Dividends — · Net buybacks 147.8

Dividends paid—

Net buybacksUSD 147.8M

Share of profit2101.6%

Consecutive raises—

USD 147.8M in buybacks — 2102% of the year's profit, so the payout drew on cash built up earlier.

Total assetsUSD 1.3B

EquityUSD 693.1M

CashUSD 158.5M

Gross debtUSD 372.2M

Net debtUSD 213.6M

Current ratio4.54×

Net debt stands at 31% of equity.

The 17-year record

17 fiscal years

Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative

Metric	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009
Revenue $B	0.7	0.7	0.7	0.7	0.5	0.4	0.4	0.3	0.3	0.3	0.2	0.2	0.1	0.0	0.0	0.0	0.0
Operating income $B	0.0	−0.1	0.1	0.1	0.1	0.0	0.0	0.0	−0.0	−0.0	0.0	−0.0	−0.1	−0.0	−0.0	−0.0	−0.0
EBITDA $B	0.1	0.0	0.2	0.2	0.1	0.1	0.0	0.0	−0.0	−0.0	0.0	0.0	−0.0	−0.0	−0.0	−0.0	−0.0
Income tax $B	0.0	0.0	0.0	−0.0	0.0	−0.1	0.0	0.0	0.0	0.0	0.0	0.0	−0.0	0.0	0.0	·	·
Net income $B	0.0	−0.1	0.0	0.0	0.0	0.1	−0.0	−0.0	−0.0	−0.0	0.0	−0.0	−0.1	−0.1	−0.0	−0.0	−0.0
Free cash flow $B	0.1	0.2	0.1	0.1	0.1	0.0	0.1	0.0	−0.0	0.0	−0.0	0.0	−0.1	−0.1	−0.0	−0.0	−0.0
EPS, diluted $	0.16	−2.15	0.89	0.34	0.92	3.33	−0.27	−0.01	−1.07	−1.02	0.04	−0.39	−1.93	−1.72	−2.64	−47.29	−55.32
Dividend / sh $	·	·	·	·	·	·	·	·	·	·	·	·	·	·	·	·	·
Payout %	·	·	·	·	·	·	·	·	·	·	·	·	·	·	·	·	·
ROE %	1.0	−12.1	5.1	2.1	6.2	29.9	−3.3	−0.2	−17.1	−17.4	1.0	−12.9	−119.3	−91.6	·	·	·
Shares out B	0.04	0.05	0.05	0.05	0.04	0.04	0.04	0.04	0.04	0.04	0.04	0.04	0.03	0.03	0.03	0.00	·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance

Company facts, as filed

How we verify · 0 failures in 66 reconciliationsAUDITED

Reconciled in 17 of 19 fiscal years. 12 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures

ActivityPharmaceutical Preparations

Listed onNASDAQ

Incorporated inDelaware

Fiscal year endsDecember 31

Data on record since2009